67 results about "NFAT" patented technology

The invention discloses a method for testing biology activity of a PD-1 pathway inhibitor. The method comprises the steps: contacting target cells expressing alpha CD3TM and PD-L1 and effector cells expressing NFAT report genes and PD-1 with the PD-1 pathway inhibitor and testing signals of the NFAT report genes to determine the biology activity of the PD-1 pathway inhibitor.

The invention provides an isolated or purified nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12. The invention also provides a nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12, wherein the NFAT promoter is located 3′ of the nucleotide sequence encoding IL-12. Also provided are related recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. The invention further provides the use of the inventive nucleic acids or related materials in the treatment or prevention of cancer or an infectious disease in a mammal and in the induction of IL-12 expression in a mammal.

The invention relates to the field of activity detection of biological medicine, in particular to a biological activity determination method for an anti-PD-L1 monoclonal antibody. According to the method, a PD1/PD-L1 interruption detection system is used, binding of PD1 and PD-L1 protein is interrupted when the anti-PD-L1 monoclonal antibody is bound with PD-L1 expressed by target cells, a transcription factor NFAT is activated through signal transduction, expression of luciferase is started, the expression quantity of luciferase is positively correlated to the biological activity of the anti-PD-L1 monoclonal antibody, the chemiluminescence value of the anti-PD-L1 monoclonal antibody is determined after a cell lysis solution and a luciferase substrate are added, a dose-effect curve is drawn, and accordingly the biological activity of the anti-PD-L1 monoclonal antibody is determined. The method is easy to implement, strong in specificity and high in durability and has great significance on quality control and clinical application of the anti-PD-L1 monoclonal antibody.

The invention provides a tetrahydroquinoline alkaloid Malaysiensin with immunosuppression activity and a production method and application of the tetrahydroquinoline alkaloid Malaysiensin with the immunosuppression activity. The compound is obtained by conducting SFM solid medium fermentation on Streptomyces sp.DSM 4137 and separating and purifying a fermentation product. The compound can significantly inhibit ConA-induced proliferation of T cells, an immunosuppression effect of the compound is equivalent to that of an immunosuppressor cyclosporin A which is clinically and widely used, and action mechanism studies show that Malaysiensin exerts the immunosuppression activity for a targeted NFAT signal path, is an efficient immunosuppressor, and can be used for producing immunosuppressive medicines for organ transplantation and autoimmune diseases.

The invention discloses a method for determining the biological activity of an LAG3 (Lymphocyte Activation Gene-3) protein binding molecule. The method comprises the step of detecting the activity ofan anti-human LAG3 antibody by a co-expression NFAT (Nuclear Factor of Activated T cells) reporting element and Jurkat cells of human LAG3 protein under the condition of coexistence of SED and Raji cells. The method provided by the invention can be used for rapidly and accurately detecting the activity of the molecule bound with human LAG3 protein.

The invention relates to a method and a reagent for regulation and control of germ layer differentiation of an embryonic stem cell and an early embryo. The invention first reveals that activation of a Calcinuerin-NFAT signal path is closely related embryonic stem (ES) cell differentiation or self-renewal, wherein ES cell germ layer differentiation can be initiated through activation of the Calcinuerin-NFAT signal path, and ES cell self-renewal can be maintained for a long time through inhibition of the Calcinuerin-NFAT signal path.

The invention discloses an application of nitidine chloride in resisting osteoporosis and in preventing and treating bone loss diseases caused by osteoclasts; the inventor, through researches, discovers that the nitidine chloride can inhibit the formation of the osteoclasts and a bone absorption function in a dose-dependent mode for the first time; it discovers that the nitidine chloride, by intervening RANKL-activated NF-kB and NFAT signaling pathways, can develop an effect of inhibiting the osteoclasts; and by establishing an ovariectomized osteoporosis mouse model, it further provides the effect of the nitidine chloride on the osteoclasts. The nitidine chloride can be used as an ideal medicine for preventing and treating the bone loss diseases caused by the osteoclasts in the future.

The invention discloses application of micromolecule RNA (Ribose Nucleic Acid) used as an immunosuppressor, and particularly relates to application of the micromolecule RNA which has a base sequence of SEQ ID NO:1 and is used as the immunosuppressor to preparation of a medicament for treating disease caused by abnormal activation of an NFAT (Nuclear Factor Activated T Cell) signal pathway. The micromolecule RNA in the invention uses NFAT as a target, inhibits the NFAT signal pathway by inhibiting a key factor in the NFAT signal pathway, can obviously inhibit activity of NFAT and can be used as the novel immunosuppressor for treating organ transplantation rejection reaction and autoimmune diseases. The micromolecule RNA in the invention is an endogenous RNA of a human body and has low toxicity for the human body.

The invention discloses a method for measuring the activity of an anti-VEGF (Vascular Endothelial Growth Factor) antibody. An effector cell which transfects a VEGF receptor, IL-1R3, IL-1R6 and a reporter gene is taken as a detection material, anti-CD3 and anti-CD28 antibodies activate Jurkat cells, a VEGF ligand is added and is combined with a VEGFR (Vascular Endothelial Growth Factor Receptor) onthe effector cell, so that IL-1R3 and IL-1R6 in the cell mutually act to activate a downstream NFAT (Nuclear Factor of Activated T) signal path, and therefore, the reporter gene can be expressed. After the anti-VEGF antibody is added, the anti-VEGF antibody can be competitively combined with the VEGF ligand so as to block the combination of the VEGF ligand and the receptor VEGFR thereof so as toreduce a downstream reporter gene expression quantity. The method has the advantages of convenient operation step, high detection sensitivity and good accuracy, and experiment time is greatly shortened.

Provided is a method for determining immunosuppression in an individual. The method entails testing blood cells for nuclear NFkB and/or nuclear NFAT. The blood cells can be from a sample of blood from an individual. The cells can be contacted with an activating agent to obtain activated cells, and the amount of nuclear NFkB and/or NFAT can be compared to a control. An amount of nuclear NFkB and/or NFAT that is higher than the control is considered to be indicative of insufficient immunosuppression in the individual. An amount of nuclear NFkB and/or NFAT that is lower than the control is considered to be indicative of excessive immunosuppression in the individual. An amount of nuclear NFkB and/or NFAT that is the same as the control is considered to be indicative of an appropriate amount of immunosuppression in the individual.

The embodiment relates to modified cells for treating a solid tumor, a composition and a method. For example, the composition comprises inducible Fms-like tyrosine kinase 3 ligand (FLT3L) modified cells; the modified cells comprise separated polynucleotide; and the separated polynucleotide comprises polynucleotide of coded FLT3L and polynucleotide of a coded Nuclear Factor of Activated T cells (NFAT) promoter, which is operably connected.

The invention provides a screening assay for selecting inhibitors of NFAT:Transcription factor interactions. The invention also provides compositions and methods for inhibiting immune response in a subject.

The invention discloses application of kavain in preparing drug for treating osteoporosis. Impact of kavain on osteoclast differentiation, osteoclast absorption and osteoblast differentiaon is evaluated through tartrate-resistant acid phosphatase dyeing, immunofluorescence, reverse transcription-polymerase chain reaction and immunoblotting analysis. Results show that kavain inhibits RANKL inducedosteoclast by blocking NFAT and MAPK passages mediated by calcium while NF-kB is unaffected; kavain also inhibits bone resorption o osteoclast and has no obvious impact on differentiation and proliferation of osteoblast. In addition, kavain can inhibit formation of osteoclast to bone loss of ovariectomized mice. Data display that osteoclast of kavain which is a natural compound has specific effect, which shows that kavain has potential value in treating osteoporosis diseases.

The invention relates to the technical field of medicines, in particular to application of pimavanserin tartrate in preparation of a drug for treating glioma, the glioma is polymorphic glioblastoma, and the application for treating glioma at least has any one or more of the following uses: (a) inhibiting the proliferation of glioma cells; (b) inhibiting the migration of glioma cells; (c) arrestingthe tumor cell cycle at G1/S phase; and (d) inhibiting the growth of intracranial tumor cells in situ. The pimavanserin tartrate is found to be an effective NFAT signal pathway inhibitor, can inhibitE2F and MYC signal pathways and ATR and AuroraA/B signal pathways in tumor cells at the same time, has high anti-GBM activity in vivo, can effectively penetrate through a blood brain barrier (BBB) toenter the brain, can effectively inhibit growth of intracranial tumors in situ through oral administration, and is convenient to use. The invention provides a novel therapeutic drug for treating GBMtumors, which has important clinical significance.

The invention relates to a use of a CMTM1-V5 polypeptide or a CMTM1-V5 polypeptide encoding polynucleotide as a biological medicine in treatment on lymphocytic leukemia and other leukemia. The invention also relates to a use of the CMTM1-V5 polypeptide or the CMTM1-V5 polypeptide encoding polynucleotide in treatment on inflammation and autoimmune diseases through NFKB and NFAT activation inhibition. The invention also relates to a pharmaceutical composition for treating leukemia, inflammation and autoimmune diseases.

A human gene NFIF1 for suppressing the activation of NF-kB and NFAT, its cDNA sequence, the polypeptide coded by it, the process for testing its functions by dual-leuciferinase report gene method, and its application in preparing the medicines for preventing and treating inflammation, anaphylactia, autoimmunopathy, tumor etc are disclosed.

The invention provides chimeric antigen receptor T cells and application thereof. An expression vector system for preparing the chimeric antigen receptor T cells comprises a first expression vector containing a chimeric antigen receptor coding gene, a second expression vector containing a signal peptide IL-2 coding gene and an IL-7 coding gene and a third expression vector containing a NFAT regulating and controlling type promoter and a CCL19 coding gene; the NFAT regulating and controlling type promoter comprises a NFAT regulating and controlling sequence and a promoter sequence; and the NFATregulating and controlling sequence comprises a nucleic acid sequence shown in SEQ ID NO:1. According to the Chimeric antigen receptor T cells and the application thereof, the signal peptide IL-7 isreplaced with a signal peptide of a T-cell secretory protein IL-2, the expression of the T cells to CCL19 is regulated and controlled by employing the NFAT regulating and controlling type promoter, and the secretory expression of the IL-7 by CAR-T cells and the regulated and controlled type expression of CCL19 by NFAT are achieved.

The invention relates to the technical field of biology, in particular to a cell strain as well as a preparation method and application thereof, a safe port site of a cell strain genome contains an NFAT element and a reporter gene regulated by the NFAT element, and the NFAT element and the reporter gene regulated by the NFAT element are NFAT-RE-Luciferase genes. The NFAT-RE-Luciferase gene in the cell strain is integrated in the genome in a specific site, and the existing cell strain is mainly obtained through a random integration technology, so that the cell strain has remarkable genome stability, and has higher transcriptional activity and higher fluorescence level compared with the existing random integration cell line, thereby the detection stability and sensitivity of the cell strain are improved. The cell strain provided by the invention also provides a good platform and solution for biological research or drug activity detection.

The invention discloses application of R406 in promotion of somatic cell reprogramming and a reprogramming culture medium and method thereof. The molecular formula of the R406 is shown in the specification, when the R406 is actually applied, the R406 can be prepared into a reprogramming culture medium for application, namely, the SYK inhibitor R406 is added into a basic culture medium to prepare the reprogramming culture medium. The R406 inhibits a Syk-Cn-NFAT signal channel and weakens direct binding of NFATc1 to glycine, serine and threonine metabolism related genes, so that expression of the genes is promoted, the content of metabolites in metabolism of glycine, serine and threonine and a downstream cysteine metabolic pathway is increased, and the intracellular H2S level is increased. H2S accumulated in cells regulates and controls mitochondrial oxidative phosphorylation activity and redox steady state, and finally promotes chemical reprogramming.

In certain embodiments the present invention provides methods useful in the treatment of glioma, such as glioblastoma, such methods comprising administering to a subject in need thereof a CSF-IR inhibitor together with one or more additional active agents such as IGF-IR inhibitors, PI3K inhibitors, IL4 inhibitors, NFAT inhibitors, and/or Stat6 inhibitors. In certain embodiments the present invention provides pharmaceutical compositions comprising a CSF-IR inhibitor together with one or more of such additional active agents.

The present invention relates to methods and means of transport of active substances in the cell cytosol. In particular, the invention relates to means that make it possible to transport directly in the cytosol substances capable of interacting with protein systems, such as the family of nuclear factors of activated T-cells (NFATs) or nucleic acids localized in the cytosol. In particular, the invention relates to nanoconstructs useful in the treatment of inflammatory diseases, methods for their preparation, and compositions containing them.

The invention is concerned with the field of muscle growth and regeneration. More particularly, the invention provides novel methods, substances and uses for facilitating the growth or regeneration of skeletal muscles. The methods, uses and substances of the invention are useful in the treatment or prevention of degenerative-regenerative muscular disorders or in the treatment of muscle injuries. The substances provided by the invention are capable of upregulating the calcineurin-NFAT-IL-4, advantageously by inhibiting the activity of the Ras or SERCA1b gene product. Introduction of the substances provided by the invention into only a small percentage of the fibers present in a regenerating muscle facilitates the regeneration of the whole muscle concerned.

The invention relates to a Melanocortin-4 receptor (MC4R) agonist that exhibits greater induction of NFAT signaling compared to α-MSH for use in the treatment and/or prevention of a medical condition associated with MC4R deficiency in a subject having an MC4R deficiency associated with impaired Nuclear factor of activated T-cells (NFAT) signaling. The present invention further relates to an in vitro method for the diagnosis, prognosis and/or assessment of likelihood of whether a subject with, or at risk of having and/or developing, a medical condition associated with MC4R deficiency, will respond to treatment with an MC4R agonist that exhibits greater induction of NFAT signaling compared to α-MSH, the method comprising (i) providing a sample from said subject, and (ii) determining whether the subject has an MC4R deficiency associated with impaired NFAT signaling by assessing said sample, (iii) wherein the presence of an MC4R deficiency associated with impaired NFAT signaling is indicative that treatment with an MC4R agonist that exhibits greater induction of NFAT signaling compared to α-MSH will be effective in said subject.